A Phase 1/2a Open-Label, Dose-Escalation/Dose-Expansion Safety, Tolerability and Pharmacokinetic Study of IMX-110 in Patients With Advanced Solid Tumors
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 05 Jan 2018
At a glance
- Drugs IMX-110 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Immix Biopharma
- 05 Jan 2018 According to an Immix Biopharma media release, Professor de Souza from Western Sydney University is the principal investigator for this study.
- 05 Jan 2018 According to an Immix Biopharma media release, Human Research Ethics Committee (IRB) approval has been recieved for this study.
- 28 Dec 2017 New trial record